KRCelltrion, a South Korean biopharmaceutical company, reported record second-quarter sales of 1.3 trillion won ($845 million) and an operating profit of 430 billion won, surpassing its own guidance. This marks a 35.2 percent increase in revenue compared to the same period last year, driven by strong performance from new, high-margin products like Remsima, Yuflyma, and Stequyma, which accounted for over 60 percent of total sales. The company noted improvements in profitability due to reduced one-time costs from mergers, lower inventory costs, and completed development expenses. It also announced plans to expand production capacity through a new 180,000-liter facility in South Korea and a 75,000-liter expansion at its Branchburg plant in New Jersey. Management expressed confidence that these strategic moves are leading to measurable gains.
Bias read (Center): The article presents factual financial performance data and operational updates from Celltrion without overt ideological framing. While the company operates within the broader economic and regulatory environment influenced by national policies, the focus remains on corporate performance metrics and
